Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 438.72M P/E - EPS this Y -12.10% Ern Qtrly Grth -
Income -70.8M Forward P/E -5.59 EPS next Y -39.20% 50D Avg Chg 53.00%
Sales 46.02M PEG - EPS past 5Y - 200D Avg Chg 143.00%
Dividend N/A Price/Book 8.39 EPS next 5Y - 52W High Chg -1.00%
Recommedations 1.80 Quick Ratio 5.25 Shares Outstanding 52.08M 52W Low Chg 484.00%
Insider Own 0.98% ROA -17.24% Shares Float 30.35M Beta 1.68
Inst Own 104.09% ROE -39.04% Shares Shorted/Prior 6.54M/6.58M Price 12.79
Gross Margin -49.93% Profit Margin -153.84% Avg. Volume 515,188 Target Price 43.67
Oper. Margin -108.03% Earnings Date May 2 Volume 859,690 Change 0.71%
About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals, Inc. News
04/16/24 EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06:00 AM EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
03/09/24 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%
03/08/24 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
03/08/24 EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
03/07/24 Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call
03/07/24 EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023
03/07/24 Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
03/07/24 EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
03/04/24 EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
02/29/24 Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
02/29/24 Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
02/29/24 EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
02/27/24 EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
02/15/24 Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
02/13/24 Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet
02/13/24 Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength
02/03/24 EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
01/31/24 EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/29/24 EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares
EYPT Chatroom

User Image RunUpABag Posted - 17 hours ago

$EYPT 🐳🐳🐳

User Image RunUpABag Posted - 20 hours ago

$EYPT Took more

User Image OoeyGooey Posted - 21 hours ago

$EYPT Closed for +9.22%, starting to accumulate too many bio plays to keep track of and need to bank some profits 🫠

User Image nycmax2002 Posted - 22 hours ago

$EYPT that dip from OCUL was a gift. Long 500 shares at 16.50 and suprised how fast its recovering.

User Image RunUpABag Posted - 04/30/24

@Motohead125 Yup, $ELUT FDA decision this quarter along with $EYPT NPDR P2 TOPLINE DATA 📈

User Image RunUpABag Posted - 04/30/24

$EYPT 🦺💥

User Image YouVSYou Posted - 04/30/24

$EYPT $JNJ $RLYB

User Image Tshanky_ Posted - 04/30/24

$RLYB beast ticker. 2 catalysts coming this Q. Partnerships with $JNJ and $EYPT

User Image RunUpABag Posted - 04/29/24

$EYPT $ELUT Huge quarter ahead , keep an eye on these 2 👁️

User Image RunUpABag Posted - 04/29/24

$EYPT Going to explode soon , can’t wait

User Image Budmanz1 Posted - 04/29/24

$EYPT FDA meeting supposed to be last week 4/23. What happened??

User Image Pharmbird Posted - 04/26/24

$EYPT Data clean- bye bye time again

User Image rizzato Posted - 04/26/24

$EYPT great value good entry bullish let's wait another week and you can buy them at 1 usd

User Image ProfitMaker4 Posted - 04/26/24

$EYPT great value play

User Image rizzato Posted - 04/26/24

$EYPT bullish bullish bullish and drop drop drop what's is going on?

User Image Poet5 Posted - 04/25/24

$EYPT Relatively low volume with half hour to go. If we close in the green today, perhaps, a sign of bleeding halted? What bullsht! Pass the puke plate.

User Image RunUpABag Posted - 04/25/24

$EYPT Board is still very quite despite the exponential growth of Eyepoint, just wait until we are at $40-$50 SP 👁️

User Image rizzato Posted - 04/25/24

$EYPT sorry -3%

User Image rizzato Posted - 04/25/24

$EYPT nice spot , bullis , great company and we are -7% again and around -40% from 25usd sorry but something is very strange here and If I were you I was not sleeping very well

User Image RunUpABag Posted - 04/25/24

$EYPT Scooped more on that dip 💰

User Image rizzato Posted - 04/25/24

$EYPT are you sure that they will not say the product is just water?????????? again down? should we stop at 1?

User Image Poet5 Posted - 04/24/24

$EYPT This is so f overdone, it is pure puke!

User Image markovb343 Posted - 04/24/24

$EYPT I think we're getting torched because of OCUL, but OCUL's ph3 wAMD comparator doesn't make any sense. We are very, very close to where loading the truck is very attractive.

User Image Tshanky_ Posted - 04/24/24

$RLYB came all the way back. This is an entry spot. Talked to IR, and $EYPT partnership update coming this quarter

User Image rizzato Posted - 04/24/24

$EYPT everyone is bullish but the price is really horrible

User Image nycmax2002 Posted - 04/24/24

$EYPT

User Image HamburgerTim Posted - 04/24/24

$EYPT nice spot here

User Image OoeyGooey Posted - 04/24/24

$EYPT Started a position here today.

User Image Pharmbird Posted - 04/24/24

$EYPT

User Image wtzou Posted - 04/23/24

$EYPT nice bounce

Analyst Ratings
HC Wainwright & Co. Buy Mar 8, 24
Mizuho Buy Feb 16, 24
JP Morgan Overweight Jan 22, 24
HC Wainwright & Co. Buy Jan 16, 24
Capital One Overweight Dec 11, 23
Mizuho Buy Dec 7, 23
HC Wainwright & Co. Buy Dec 5, 23
HC Wainwright & Co. Buy Nov 2, 23
Mizuho Buy Nov 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Jones David Scott SVP & Chief Commerci.. SVP & Chief Commercial Officer Jan 26 Sell 25.36 26,017 659,791 37,962 01/29/24
Jones David Scott SVP & Chief Commerci.. SVP & Chief Commercial Officer Jan 26 Option 8.08 26,017 210,217 63,979 01/29/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Jan 25 Sell 25 600 15,000 36,505 01/29/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Jan 25 Option 13.02 600 7,812 37,105 01/29/24
Jones David Scott SVP & Chief Commerci.. SVP & Chief Commercial Officer Jan 24 Sell 25.01 11,900 297,619 37,962 01/26/24
Jones David Scott SVP & Chief Commerci.. SVP & Chief Commercial Officer Jan 24 Option 8.08 11,900 96,152 38,562 01/26/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Jan 23 Sell 25.01 16,386 409,814 36,505 01/25/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Jan 23 Option 13.02 16,386 213,346 47,756 01/25/24
Lurker Nancy Executive Vice Chair Executive Vice Chair Jan 23 Sell 24.97 35,000 873,950 135,441 01/25/24
Jones David Scott SVP & Chief Commerci.. SVP & Chief Commercial Officer Jan 22 Sell 23.73 35,066 832,116 37,962 01/24/24
Jones David Scott SVP & Chief Commerci.. SVP & Chief Commercial Officer Jan 22 Option 9.44 35,066 331,023 38,862 01/24/24
Ocumension Therapeutics Director Director Jan 11 Sell 19.45 1,910,500 37,159,225 100,221 01/16/24
Liu Ye Director Director Jan 11 Sell 19.45 1,910,500 37,159,225 100,221 01/16/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Jan 08 Sell 21.13 22,913 484,152 36,505 01/10/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Jan 08 Option 3.26 22,913 74,696 59,418 01/10/24
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Dec 13 Sell 20 1,458 29,160 25,707 12/15/23
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Dec 13 Option 10.13 1,458 14,770 27,165 12/15/23
Ocumension Therapeutics Director Director Dec 05 Sell 19.16 1,000,000 19,160,000 2,010,721 12/07/23
Liu Ye Director Director Dec 05 Sell 19.16 1,000,000 19,160,000 2,010,721 12/07/23
Pine Michael Craig Chief Corp Dev.&Stra.. Chief Corp Dev.&Strat. Officer Dec 04 Sell 22 45,000 990,000 5,343 12/06/23
Pine Michael Craig Chief Corp Dev.&Stra.. Chief Corp Dev.&Strat. Officer Dec 04 Option 12.62 45,000 567,900 50,343 12/06/23
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Dec 04 Sell 22 30,625 673,750 25,707 12/06/23
Paggiarino Dario A. Chief Medical Office.. Chief Medical Officer Dec 04 Option 10.13 30,625 310,231 56,332 12/06/23
Lurker Nancy Executive Vice Chair Executive Vice Chair Dec 04 Sell 20.76 20,000 415,200 170,559 12/06/23
Cormorant Asset Management, LP 10% Owner 10% Owner Dec 04 Buy 26.82 1,919,057 51,469,109 5,450,000 12/06/23
EW Healthcare Partners, L.P. 10% Owner 10% Owner Sep 01 Sell 9.8991 20,000 197,982 3,490,921 09/06/23
EW Healthcare Partners, L.P. 10% Owner 10% Owner Aug 30 Sell 10.87 139,471 1,516,050 3,510,921 09/01/23
EW Healthcare Partners, L.P. 10% Owner 10% Owner Aug 28 Sell 11.34 148,712 1,686,394 3,650,392 08/30/23
EW Healthcare Partners, L.P. 10% Owner 10% Owner Aug 24 Sell 10.91 223,936 2,443,142 3,799,104 08/30/23
EW Healthcare Partners, L.P. 10% Owner 10% Owner Aug 22 Sell 13.84 167,881 2,323,473 4,023,040 08/24/23
Zaderej Karen L. Director Director Jul 11 Option 0.00 2,000 2,000 07/12/23
ADAMIS ANTHONY P Director Director Jun 23 Option 0.00 2,000 2,000 06/26/23
Liu Ye Director Director May 30 Sell 6.00 1 6 3,010,721 05/31/23
Lurker Nancy President & CEO President & CEO Feb 28 Option 0.00 12,466 150,281 03/02/22
Landis John B. Director Director Feb 09 Option 0.00 2,500 8,400 02/11/22
GUYER DAVID R Director Director Feb 09 Option 0.00 2,500 4,400 02/11/22
DICICCO WENDY F Director Director Feb 09 Option 0.00 2,500 4,400 02/11/22
ANDO GORAN Director Director Feb 09 Option 0.00 2,750 4,900 02/11/22